Indaptus Therapeutics (NASDAQ:INDP) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reissued their buy rating on shares of Indaptus Therapeutics (NASDAQ:INDP) in a research note released on Monday morning, Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright also issued estimates for Indaptus Therapeutics’ Q1 2024 earnings at ($0.57) EPS, Q2 2024 earnings at ($0.60) EPS, Q4 2024 earnings at ($0.34) EPS, FY2024 earnings at ($1.83) EPS, Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS and FY2025 earnings at ($1.44) EPS.

Indaptus Therapeutics Trading Down 5.3 %

Shares of NASDAQ:INDP opened at $2.52 on Monday. The firm has a market capitalization of $21.52 million, a PE ratio of -1.37 and a beta of 1.28. Indaptus Therapeutics has a 1-year low of $1.56 and a 1-year high of $4.08. The business’s 50 day moving average is $2.15 and its 200-day moving average is $2.11.

Indaptus Therapeutics (NASDAQ:INDP) last announced its quarterly earnings results on Wednesday, March 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. On average, sell-side analysts predict that Indaptus Therapeutics will post -1.83 EPS for the current year.

Institutional Investors Weigh In On Indaptus Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in shares of Indaptus Therapeutics by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 256,265 shares of the company’s stock worth $451,000 after buying an additional 5,517 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Indaptus Therapeutics in the 4th quarter valued at $29,000. Renaissance Technologies LLC bought a new stake in shares of Indaptus Therapeutics in the 2nd quarter worth about $51,000. State Street Corp acquired a new stake in shares of Indaptus Therapeutics during the 1st quarter worth about $78,000. Finally, Northern Trust Corp bought a new position in Indaptus Therapeutics during the 1st quarter valued at about $41,000. 7.06% of the stock is owned by institutional investors and hedge funds.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.